Company news
Trevi Therapeutics, Inc. news in 2023
Trevi Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
December 4, 2023
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
November 8, 2023
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
November 1, 2023
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
October 31, 2023
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
October 12, 2023
Trevi Therapeutics to Participate in Upcoming September Events
September 5, 2023
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023
August 2, 2023
Trevi Therapeutics to Participate in Upcoming August Events
July 31, 2023
Trevi Therapeutics to Participate in Upcoming July Investor Events
July 5, 2023
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
May 21, 2023
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
May 8, 2023
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023
May 3, 2023
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
May 1, 2023
Trevi Therapeutics to Participate in Upcoming May Investor Events
April 26, 2023
Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
March 15, 2023
Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023
March 8, 2023
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
March 7, 2023
Trevi Therapeutics to Participate in Upcoming March Conferences
March 5, 2023
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
February 15, 2023
Trevi Therapeutics to Present and Participate in Upcoming February Conferences
February 1, 2023
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences
January 4, 2023
Calls in 2023
Decks in 2023
- Technical Presentation (May 2023)
Technical · 14 slides · May 22, 2023